Journal article
Bioavailability of Iron in Hemodialysis Patients Treated With Erythropoietin: Evidence for the Inhibitory Role of Aluminum
Abstract
The dose of recombinant human erythropoietin (r-HuEPO) required to correct the anemia of end-stage renal disease (ESRD) varies among patients. The response to r-HuEPO is impaired if absolute or relative iron deficiency exists. Aluminum may cause a microcytic anemia in patients with ESRD, but the mechanism remains incompletely defined. Twenty-two patients in the Canadian Multicentre EPO trial were studied for 6 months. In this randomized …
Authors
Donnelly SM; Ali MAM; Churchill DN
Journal
American Journal of Kidney Diseases, Vol. 16, No. 5, pp. 447–451
Publisher
Elsevier
Publication Date
11 1990
DOI
10.1016/s0272-6386(12)80057-6
ISSN
0272-6386